Barras M - Search Results

1

Experiences and learnings of pharmacists, students, and clinical assistants working collaboratively in a COVID-19 vaccination clinic: a qualitative study.

Paradissis C, De Guzman KR, Barras M, La Caze A, Winckel K, Taufatofua N, Falconer N. Paradissis C, et al. Among authors: barras m. Explor Res Clin Soc Pharm. 2023 Mar;9:100241. doi: 10.1016/j.rcsop.2023.100241. Epub 2023 Mar 8. Explor Res Clin Soc Pharm. 2023. PMID: 36923065 Free PMC article.

2

Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins.

Al-Sallami HS, Barras MA, Green B, Duffull SB. Al-Sallami HS, et al. Clin Pharmacokinet. 2010 Sep;49(9):567-71. doi: 10.2165/11532960-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20690780

3

Hospital pharmacists' perceptions of medication counseling: A focus group study.

Chevalier BA, Watson BM, Barras MA, Cottrell WN. Chevalier BA, et al. Among authors: barras ma. Res Social Adm Pharm. 2016 Sep-Oct;12(5):756-71. doi: 10.1016/j.sapharm.2015.10.007. Epub 2015 Oct 30. Res Social Adm Pharm. 2016. PMID: 26626591

4

Systematic review of predictive risk models for adverse drug events in hospitalized patients.

Falconer N, Barras M, Cottrell N. Falconer N, et al. Among authors: barras m. Br J Clin Pharmacol. 2018 May;84(5):846-864. doi: 10.1111/bcp.13514. Epub 2018 Feb 22. Br J Clin Pharmacol. 2018. PMID: 29337387 Free PMC article.

5

Reply to Iuga and Genaidy 'Comment on Falconer et al. (2018) - the need for specific adverse drug reaction outcomes'.

Falconer N, Barras M, Cottrell N. Falconer N, et al. Among authors: barras m. Br J Clin Pharmacol. 2018 Aug;84(8):1857. doi: 10.1111/bcp.13633. Epub 2018 Jun 5. Br J Clin Pharmacol. 2018. PMID: 29873096 Free PMC article. No abstract available.

6

Defining and classifying terminology for medication harm: a call for consensus.

Falconer N, Barras M, Martin J, Cottrell N. Falconer N, et al. Among authors: barras m. Eur J Clin Pharmacol. 2019 Feb;75(2):137-145. doi: 10.1007/s00228-018-2567-5. Epub 2018 Oct 11. Eur J Clin Pharmacol. 2019. PMID: 30310967 Review.

7

How hospital pharmacists prioritise patients at high-risk for medication harm.

Falconer N, Barras M, Cottrell N. Falconer N, et al. Among authors: barras m. Res Social Adm Pharm. 2019 Oct;15(10):1266-1273. doi: 10.1016/j.sapharm.2018.11.003. Epub 2018 Nov 8. Res Social Adm Pharm. 2019. PMID: 30466812

8

Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.

van Oosterom N, Winckel K, Barras M. van Oosterom N, et al. Among authors: barras m. J Thromb Thrombolysis. 2019 Oct;48(3):387-393. doi: 10.1007/s11239-019-01847-4. J Thromb Thrombolysis. 2019. PMID: 30945098

9

Comment On: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".

van Oosterom N, Winckel K, Barras M. van Oosterom N, et al. Among authors: barras m. Clin Drug Investig. 2020 Mar;40(3):287-288. doi: 10.1007/s40261-020-00889-4. Clin Drug Investig. 2020. PMID: 32016715 No abstract available.

10

Unfractionated heparin dosing in obese patients.

George C, Barras M, Coombes J, Winckel K. George C, et al. Among authors: barras m. Int J Clin Pharm. 2020 Apr;42(2):462-473. doi: 10.1007/s11096-020-01004-5. Epub 2020 Mar 5. Int J Clin Pharm. 2020. PMID: 32140914

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters